NCT03650348View on ClinicalTrials.gov

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 21, 2018

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder CancerHER2-positive Solid Tumor
Interventions
DRUG

PRS-343 in Combination with Atezolizumab

HER2/4-1BB Bispecific

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

43202

The Ohio State University Comprehensive Cancer Center, Columbus

70121

Ochsner Cancer Institute, New Orleans

77030

M.D. Anderson Cancer Center, Houston

78240

NEXT Oncology, San Antonio

90033

USC Norris Comprehensive Cancer Center, Los Angeles

90404

UCLA Health, Santa Monica

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
lead

Pieris Pharmaceuticals, Inc.

INDUSTRY

NCT03650348 - PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | Biotech Hunter | Biotech Hunter